VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease

被引:73
作者
Fragoso, R
Pereira, T
Wu, Y
Zhu, ZP
Cabeçadas, J
Dias, S
机构
[1] IPOFG, Angiogenesis Lab, Ctr Invest Patobiol Mol, P-1099023 Lisbon, Portugal
[2] IPOFG, Serv Anat Patol, P-1099023 Lisbon, Portugal
[3] Inst Mol Med, Fac Med, Lisbon, Portugal
[4] Gulbenkian Inst Sci, Oeiras, Portugal
[5] ImClone Syst, New York, NY USA
关键词
D O I
10.1182/blood-2005-06-2530
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The presence of persistent circulating leukemia cells, or engrafted into extramedullary tissues, is a bad prognostic factor for patients with acute leukemia. However, little is known about the mechanisms that regulate the exit of leukemia cells from the bone marrow (BM) microenvironment. We reveal that vascular endothelial growth factor receptor 1 (FLT-1) modulates acute leukemia distribution within the BM, along VEGF and PIGF gradients, regulating leukemia survival and exit into the peripheral circulation. FLT-1 activation on acute lymphoblastic leukemia (ALL) cells results in cell migration and proliferation in vitro, whereas in vivo FLT-1-overexpressing cells accumulate in the BM epiphysis of nonobese diabetic-severe combined immunodeficient (NOD-SCID) recipients and are detected in circulation 2 weeks after inoculation. In turn, FLT-1 neutralization affects leukemia localization (now in the BM diaphysis), increases leukemia apoptosis, and impedes the exit of ALL cells, prolonging the survival of inoculated mice. We demonstrate further that FLT-1-induced cell migration involves actin polymerization and lipid raft formation. Taken together, we show that FLT-1 regulates the BM localization of ALL cells, determining their survival and exit into the circulation and ultimately the survival of inoculated recipients. FLT-1 targeting on subsets of acute leukemias may delay the onset of extramedullary disease, which may be advantageous in combinatorial therapeutic settings.
引用
收藏
页码:1608 / 1616
页数:9
相关论文
共 35 条
[1]   Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].
Aguayo, A ;
Kantarjian, H ;
Manshouri, T ;
Gidel, C ;
Estey, E ;
Thomas, D ;
Koller, C ;
Estrov, Z ;
O'Brien, S ;
Keating, M ;
Freireich, E ;
Albitar, M .
BLOOD, 2000, 96 (06) :2240-2245
[2]   Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes [J].
Aguayo, A ;
Giles, F ;
Albitar, M .
LEUKEMIA & LYMPHOMA, 2003, 44 (02) :213-222
[3]  
[Anonymous], TXB SMALL ANIMAL ORT
[4]   Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes [J].
Bellamy, WT ;
Richter, L ;
Sirjani, D ;
Roxas, C ;
Glinsmann-Gibson, B ;
Frutiger, Y ;
Grogan, TM ;
List, AF .
BLOOD, 2001, 97 (05) :1427-1434
[5]   Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration [J].
Dias, S ;
Hattori, K ;
Zhu, ZP ;
Heissig, B ;
Choy, M ;
Lane, W ;
Wu, Y ;
Chadburn, A ;
Hyjek, E ;
Gill, M ;
Hicklin, DJ ;
Witte, L ;
Moore, MAS ;
Rafii, S .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (04) :511-521
[6]   VEGF165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition [J].
Dias, S ;
Shmelkov, SV ;
Lam, G ;
Rafii, S .
BLOOD, 2002, 99 (07) :2532-2540
[7]   Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy [J].
Dias, S ;
Choy, M ;
Alitalo, K ;
Rafii, S .
BLOOD, 2002, 99 (06) :2179-2184
[8]   Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia - A report from the children's cancer group [J].
Dusenbery, KE ;
Howells, WB ;
Arthur, DC ;
Alonzo, T ;
Lee, JW ;
Kobrinsky, N ;
Barnard, DR ;
Wells, RJ ;
Buckley, JD ;
Lange, BJ ;
Woods, WG .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (10) :760-768
[9]   Vascular endothelial growth factor: Basic science and clinical progress [J].
Ferrara, N .
ENDOCRINE REVIEWS, 2004, 25 (04) :581-611
[10]  
Gajjar A, 2000, BLOOD, V96, P3381